skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Leukocyte peroxidase and leptin: an associated link of glycemic tolerance and bronchial asthma?

Rapid Communication

(2145) Views  (657) Full article downloads

Authors: Sergio Parco

Published Date May 2010 Volume 2010:3 Pages 113 - 116
DOI: http://dx.doi.org/10.2147/DMSO.S8504

Sergio Parco

Immunopathology Unit, Laboratory of the Department of Medicine, Children’s Hospital, IRCCS Burlo Garofolo, Trieste, Italy

Abstract: Recent observations suggest the presence of an interaction between leptin and the inflammatory system during bronchial asthma. Although there is evidence of a positive association between asthma and obesity in adults and children, little is yet known about the role of serum leptin, as a potential mediator for bronchial epithelial homeostasis, and intraleukocyte myeloperoxidase (MPO), a hemoprotein with a molecular weight of 140 kDa, expression of the inflammatory system, in asthmatic children. Glycemic tolerance is an important pathogenetic element in developing type 2 mellitus diabetes and a confirmed predictor of incident asthma-like symptoms in adults. This work is aimed at assessing a possible correlation between basal leukocyte myeloperoxidase levels, basal leptin and insulin-glycemic tolerance in obese children. Thirty obese children aged between 7 and 15 years were examined. The analyzed data showed a normal response to the insulinemic stimulus in children of both sexes whose basal leptin and MPO values, expressed as MPO intracellular index, werewithin the normal range.

Keywords: leptin, myeloperoxidase, glycemic tolerance, asthma






 

Other articles by Dr Sergio Parco



Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Risk management in the treatment of type 2 diabetes with pioglitazone
Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives
Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment
Tackling obesity: new therapeutic agents for assisted weight loss
New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio